Amgen Stock News

Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.

Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take direct aim at drug imports. The post Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports appeared first on Investor's Business Daily.

Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.

What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.

One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.